Spero Therapeutics Inc
SPRO2.500USD
+0.370+17.37%
Fechamento 05/30, 16:00（ET）Cotações atrasadas em 15 min
139.75MValor de mercado
PerdaP/L TTM
Mais detalhes de Spero Therapeutics Inc Empresa
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Informações da empresa
Código da empresaSPRO
Nome da EmpresaSpero Therapeutics Inc
Data de listagemNov 02, 2017
Fundado em2013
CEOMs. Esther Rajavelu
Número de funcionários32
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 02
Endereço675 Massachusetts Ave Ste 14
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02139-3309
Telefone18572421600
Sitehttps://sperotherapeutics.com/
Código da empresaSPRO
Data de listagemNov 02, 2017
Fundado em2013
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
350.79K
+112.94%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
+38.87%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
+57.14%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
+57.14%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
+57.14%
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Dr. Patrick Volkert Jo Vink, M.D.
Dr. Patrick Volkert Jo Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
350.79K
+112.94%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
+38.87%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
+57.14%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
+57.14%
Detalhamento da receita
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
47.98M
0.00%
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: sex, 16 de mai
Tempo de atualização: sex, 16 de mai
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
Estatísticas dos acionistas
Acionista
Proporção
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
Tipo
Acionista
Proporção
Corporation
20.66%
Hedge Fund
10.30%
Investment Advisor/Hedge Fund
8.22%
Individual Investor
3.66%
Venture Capital
2.58%
Investment Advisor
2.01%
Research Firm
0.14%
Other
52.43%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
114
27.91M
50.02%
+3.00M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
2023Q2
230
24.99M
47.83%
-1.96M
2023Q1
242
24.74M
47.38%
-2.46M
2022Q4
247
26.52M
54.04%
-1.18M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
GSK plc
9.19M
16.44%
--
--
Mar 27, 2025
Anson Funds Management LP.
3.84M
6.87%
+89.44K
+2.38%
Dec 31, 2024
Pfizer Inc
2.36M
4.23%
+2.36M
--
Dec 31, 2024
The Vanguard Group, Inc.
1.76M
3.15%
--
--
Dec 31, 2024
Renaissance Technologies LLC
1.11M
1.98%
+130.94K
+13.43%
Dec 31, 2024
Alphabet, Inc.
889.98K
1.59%
--
--
Dec 31, 2024
Murchinson Ltd.
873.91K
1.56%
+873.91K
--
Dec 31, 2024
Acadian Asset Management LLC
1.04M
1.86%
-31.94K
-2.98%
Dec 31, 2024
Adar1 Capital Management LLC
801.28K
1.43%
+57.82K
+7.78%
Dec 31, 2024
Hamed (Kamal)
788.12K
1.41%
+211.66K
+36.72%
Feb 02, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: ter, 6 de mai
Tempo de atualização: ter, 6 de mai
Nome
Proporção
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
iShares Micro-Cap ETF
Proporção0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Royce Quant Small-Cap Quality Value ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
